Pfizer scores FDA nod for biosim to AbbVie's Humira, but it'll have to wait till 2023 to launch

Pfizer
Pfizer is planning three biosim launches for the next few months. (Pfizer)

AbbVie is preparing for the costly U.S. loss of Humira exclusivity in 2023, and now there’s another pharma giant that has scored a biosimilar nod.

Pfizer’s Abrilada, a biosim to AbbVie’s megablockbuster Humira, won FDA approval Monday, becoming the 25th biosim to score a green light from the agency. And like many in that group, Abrilada will have to wait to launch due to patent issues. 

Pfizer last November inked a patent deal with AbbVie to allow for a 2023 biosimilar launch, joining other companies in making patent settlements with AbbVie rather than litigating a complex web of patents.

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

Abrilada won FDA approval to treat various inflammatory diseases treated by Humira. The company said it’ll provide more details about launch plans as the rollout nears. Meanwhile, the company has three biosim launches set for the next few months, CEO Albert Bourla said on a recent conference call. Pfizer plans to take on a trio of Roche drugs, launching its Avastin biosimilar on Dec. 31, followed by its Rituxan biosim in January and its Herceptin biosim in February.

RELATED: AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023 

Under AbbVie’s existing patent deals with copycats, Amgen will have the chance to launch the first U.S. Humira biosimilar in 2023.  

Meanwhile, Humira biosims to the drug are already rolling in Europe, stealing market share and driving prices lower. AbbVie generated nearly $20 billion in Humira sales last year, and the drugmaker has agreed to acquire Allergan to shore up its future beyond the med’s U.S. loss of exclusivity.  

Read more on

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.